US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

NeoGenomics, Inc. - Common Stock (NQ:NEO)

19.13 +0.66 (+3.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports Second Quarter 2026 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports First Quarter 2026 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present New ctDNA Research at SABCS 2025
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >